Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor. 1995

K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
Department of Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.

A type I ribosome inactivating protein, gelonin, was linked to Lym-1, a murine monoclonal antibody reactive with a polymorphic determinant of class II HLA-DR histocompatibility leukocyte antigen (HLA) on human lymphoma cells, via a disulfide linkage using the heterobifunctional cross-linking agent, N-succinimidyl-3-(2-pyridyldithio) propionate. This immunotoxin was purified from unreacted gelonin and unconjugated Lym-1 by fast protein liquid chromatography using sephacryl S-300 gel filtration and blue sepharose affinity gradient separation. Binding of Lym-1-gelonin immunoconjugate to human Raji Burkitt's lymphoma cells was demonstrated by indirect immunofluorescence using flow cytometry. Lym-1-gelonin was very active in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium salt and sulforhodamine B in vitro cytotoxicity assays against the Raji lymphoma cell line and confirmed the fact that monoclonal antibody Lym-1 internalizes into human lymphoma cells. A weaker cytostatic antiproliferative effect was also noted for unconjugated Lym-1. gamma-interferon augmented the antiproliferative effects of Lym-1-gelonin conjugate and unconjugated Lym-1, by having a direct cytotoxic effect on the Raji cells. Tumor necrosis factor-alpha also enhanced the antiproliferative effect of unconjugated Lym-1, but did not significantly augment the cytotoxic activity of the Lym-1-gelonin conjugate. These results suggest that anti-HLA class II monoclonal antibodies may be useful in constructing immunotoxins for the treatment of human lymphomas and leukemias expressing HLA class II antigens, and that unconjugated anti-HLA class II monoclonal antibodies may be therapeutically useful in conjunction with recombinant cytokines, especially gamma-interferon.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D010940 Plant Proteins Proteins found in plants (flowers, herbs, shrubs, trees, etc.). The concept does not include proteins found in vegetables for which PLANT PROTEINS, DIETARY is available. Plant Protein,Protein, Plant,Proteins, Plant
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002477 Cells The fundamental, structural, and functional units or subunits of living organisms. They are composed of CYTOPLASM containing various ORGANELLES and a CELL MEMBRANE boundary. Cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
January 1997, Oncology reports,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
May 1998, Japanese journal of cancer research : Gann,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
March 1989, Molecular and cellular biology,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
April 1991, International journal of pancreatology : official journal of the International Association of Pancreatology,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
December 1989, Journal of biological response modifiers,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
January 1988, Pancreas,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
November 1992, Archives of otolaryngology--head & neck surgery,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
April 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
October 1999, Cancer biotherapy & radiopharmaceuticals,
K P O'Boyle, and D Colletti, and C Mazurek, and Y Wang, and S K Ray, and B Diamond, and M G Rosenblum, and A L Epstein, and D Shochat, and J P Dutcher
April 1990, Journal of interferon research,
Copied contents to your clipboard!